Sarcopenia, Muscle weakness, Decrease of muscle strength. Muscle wasting and atrophy, not elsewhere classified
Conditions
Interventions
Vitamin D supplement in a DRI dose.
Prevention
Vitamin D supplement in a DRI dose
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
40 Years to 55 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Healthy? aged 40-55 years old women; Premenopaused; BMI 18.5-29.9 kg/m2; 25(OH)-D<25 nmol/l; Not ovariectomized; Women must be with out following diseases: uncontrolled hypertension; diabetes; cardiovascular diseases; renal disorders; asthma; liver diseases; thyroid or parathyroid diseases; bone disorders; gastrointestinal diseases; infectious diseases and hyperphosphatemia; Not taking W3 fatty acids or fish oil; hormonal products? any supplements including vitamins and minerals; Not using one of the following medications: anti inflammatory drugs (including NSAIDs and steroids); phenobarbital? phenytoin; anti acid drugs? diuretics and laxative drugs; Not using any drug and supplement have effect on weight status; Voluntary participitation. Exclusion criteria: Acute disease; Migration; Any event that effect on health status
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement of muscle strength in hand and foot, Improvement of body composition. Timepoint: 12 weeks. Method of measurement: Dynamometer, Handgrip, BIA. | — |
Secondary
| Measure | Time frame |
|---|---|
| Increase of serum 25(OH)-D. Timepoint: 12 weeks. Method of measurement: Laboratory Kit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Mohammad Reza Vafa
Iran University of Medical Sciences
Outcome results
None listed